Page last updated: 2024-11-04

vorinostat and Cell Transformation, Neoplastic

vorinostat has been researched along with Cell Transformation, Neoplastic in 10 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.

Research Excerpts

ExcerptRelevanceReference
"Treatment with Vorinostat/JQ1 inhibited glycolysis/MTOR signaling, activated the clock, and upregulated the UPR and autophagy via inhibition of YAP1/NF-κB."1.48YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma. ( Babichev, Y; C Brady, D; Chor, S; E Ciotti, G; E Marino, G; Egolf, S; Eisinger-Mathason, TSK; Gladdy, R; Koumenis, C; Leli, NM; Liu, Y; Mancuso, A; Pak, K; Park, PMC; Posimo, JM; Qi, J; Rivera-Reyes, A; Sostre-Colón, J; Tameire, F; Weber, K; Ye, S, 2018)
"DER significantly reduced mammary cancer incidence, multiplicity, and cancer burden and prolonged cancer latency (P < 0."1.39Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model. ( Jiang, W; McGinley, JN; Thompson, HJ; Zhu, Z, 2013)
" The present results show the applicability of our novel statistical methodology for quantitatively assessing drug synergy across a wide range of doses of agents with complex dose-response profiles, a methodology with great potential for advancing the development of chemopreventive combinations."1.36Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. ( Fujimoto, J; Hong, WK; Kong, M; Lee, JJ; Lotan, R, 2010)
"HDACis are a group of novel anticancer agents."1.34Histone deacetylase inhibitors selectively suppress expression of HDAC7. ( Clarke, C; Dokmanovic, M; Marks, PA; Ngo, L; Parmigiani, RB; Perez, G; Xu, W, 2007)
"Murine erythroleukemia cells developed for resistance to SAHA are cross-resistant to trichostatin A, a known deacetylase inhibitor and differentiation inducer, but are not cross-resistant to HMBA."1.30A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. ( Breslow, R; Emiliani, S; Marks, PA; Richon, VM; Rifkind, RA; Verdin, E; Webb, Y, 1998)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's2 (20.00)29.6817
2010's6 (60.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Chhabra, R1
Rockfield, S1
Guergues, J1
Nadeau, OW1
Hill, R1
Stevens, SM1
Nanjundan, M1
Ye, S2
Lawlor, MA1
Rivera-Reyes, A2
Egolf, S2
Chor, S2
Pak, K2
Ciotti, GE1
Lee, AC1
Marino, GE1
Shah, J1
Niedzwicki, D1
Weber, K2
Park, PMC2
Alam, MZ1
Grazioli, A1
Haldar, M1
Xu, M1
Perry, JA1
Qi, J2
Eisinger-Mathason, TSK2
E Marino, G1
E Ciotti, G1
Liu, Y1
Posimo, JM1
Babichev, Y1
Sostre-Colón, J1
Tameire, F1
Leli, NM1
Koumenis, C1
C Brady, D1
Mancuso, A1
Gladdy, R1
Ge, Y1
Gong, Z1
Olson, JR1
Xu, P1
Buck, MJ1
Ren, X1
Fujimoto, J1
Kong, M1
Lee, JJ1
Hong, WK1
Lotan, R1
Xu, S1
De Becker, A1
De Raeve, H1
Van Camp, B1
Vanderkerken, K1
Van Riet, I1
Zhu, Z1
Jiang, W1
McGinley, JN1
Thompson, HJ1
Ogawa, T1
Hayashi, T1
Tokunou, M1
Nakachi, K1
Trosko, JE1
Chang, CC1
Yorioka, N1
Dokmanovic, M1
Perez, G1
Xu, W1
Ngo, L1
Clarke, C1
Parmigiani, RB1
Marks, PA2
Richon, VM1
Emiliani, S1
Verdin, E1
Webb, Y1
Breslow, R1
Rifkind, RA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900]Phase 16 participants (Actual)Interventional2016-03-31Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

10 other studies available for vorinostat and Cell Transformation, Neoplastic

ArticleYear
Global miRNA/proteomic analyses identify miRNAs at 14q32 and 3p21, which contribute to features of chronic iron-exposed fallopian tube epithelial cells.
    Scientific reports, 2021, 03-18, Volume: 11, Issue:1

    Topics: Azacitidine; Biomarkers, Tumor; Cell Line, Transformed; Cell Transformation, Neoplastic; Down-Regula

2021
YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.
    Cancer research, 2018, 05-15, Volume: 78, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Angiomotins; Animals; Antineoplastic Agents; Azepines; Cell Cy

2018
YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma.
    Cell death & disease, 2018, 10-31, Volume: 9, Issue:11

    Topics: Activating Transcription Factor 6; Adaptor Proteins, Signal Transducing; Animals; Autophagy; Azepine

2018
Inhibition of monomethylarsonous acid (MMA(III))-induced cell malignant transformation through restoring dysregulated histone acetylation.
    Toxicology, 2013, Oct-04, Volume: 312

    Topics: Acetylation; Cell Transformation, Neoplastic; Cells, Cultured; Histone Deacetylase 1; Histone Deacet

2013
Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention.
    Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:8

    Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Prol

2010
In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.
    Biochemical and biophysical research communications, 2012, Aug-03, Volume: 424, Issue:3

    Topics: Animals; Antigens, CD34; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Transformation, Neoplast

2012
Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model.
    Cancer prevention research (Philadelphia, Pa.), 2013, Volume: 6, Issue:4

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Caloric Restriction; Cell Transformation, Neoplast

2013
Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
    Cancer research, 2005, Nov-01, Volume: 65, Issue:21

    Topics: Acetylation; Animals; Apoptosis; Cell Communication; Cell Growth Processes; Cell Transformation, Neo

2005
Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:9

    Topics: Acetylation; Blotting, Northern; Blotting, Western; Cell Transformation, Neoplastic; Cyclin-Dependen

2007
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.
    Proceedings of the National Academy of Sciences of the United States of America, 1998, Mar-17, Volume: 95, Issue:6

    Topics: Acetamides; Animals; Carcinoma; Cell Differentiation; Cell Line, Transformed; Cell Transformation, N

1998